Clinical trial
A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188 is registered in ClinicalTrials.gov with Zhao Minghui as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
- Lead sponsor
- Zhao Minghui
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- September 10, 2026
- Completion date
- May 8, 2029
- Enrollment
- 70 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.